Makary lauds user fees as FDA begins GDUFA IV reauthorization process
Regulatory NewsMichael Mezher
GDUFAGenericsProduct LifecycleUnited StatesUS Food and Drug Administration (FDA)User feesRegulatory NewsMichael MezherGDUFAGenericsProduct LifecycleUnited StatesUS Food and Drug Administration (FDA)User fees